IP Library Granted Patent US 10,130,765
Granted Patent B2
US 10,130,765 · App. 14/077,181 · Granted Nov 20, 2018

Integrated insulin delivery system having safety features to prevent hypoglycemia

Inventors: Erwin S. Budiman (Fremont, CA); Gary A. Hayter (Oakland, CA); Nathan Crouther (Camarillo, CA); Marc B. Taub (Mountain View, CA); Wesley Scott Harper (Alameda, CA); Charles Wei (Fremont, CA)
Assignee: Abbott Diabetes Care Inc.
A61M5/1723A61B5/1495A61B5/14532A61B5/4839G06F19/00G06F19/3468A61B2562/0295A61M2005/14208A61M2005/14296A61M2205/3569A61M2205/52A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,130,765
App. No.
14/077,181
Filed
Nov 11, 2013
Granted
Nov 20, 2018
Kind
B2
Art Unit
3783
USPC
604/66
Abstract

Safety features are applied to an integrated insulin delivery system to enhance safety by controlling medication delivery including the automatic resumption of basal rate after a particular event, such as termination of a bolus, expiration of a time period, delayed resumption after the bolus has terminated, IOB comparison, and others. Other safety features include overriding a delivery control that may result in hypoglycemia, and terminating an extended bolus or temporary basal rate in view of a glucose signal indicating imminent carbohydrate deficiency. In another feature, an automatic resumption of a basal delivery rate is programmed into the delivery device to avoid the possibility of complete loss of delivery of insulin in the event that communication with the delivery device is disrupted.

Claims (18)

1. A system for the delivery of insulin to a patient, the system comprising:

a continuous glucose sensor configured to provide a glucose level signal representative of sensed glucose;

an insulin delivery device configured to deliver insulin in response to delivery control signals at a programmed basal rate and as a bolus; and

a controller programmed to receive the sensor glucose level signal and to provide a delivery control signal to the insulin delivery device to deliver the bolus and to set the programmed basal rate to zero for a predetermined period of time after commencement of the bolus delivery.

2. The system of claim 1 wherein the predetermined period of time is based upon an amount of insulin delivered in a preceding closed-loop cycle.

3. The system of claim 1 wherein the predetermined period of time is based upon a level of insulin on board (IOB) and the programmed basal delivery rate.

4. The system of claim 1 , wherein the bolus is an extended bolus.

5. The system of claim 4 , wherein the controller is further programmed to interrupt the extended bolus.

6. The system of claim 4 , wherein the controller is further programmed to interrupt the extended bolus if the patient is in a carbohydrate deficient state.

7. A system for the delivery of insulin to a patient, the system comprising:

a continuous glucose sensor configured to provide a glucose level signal representative of sensed glucose;

an insulin delivery device configured to deliver insulin in response to delivery control signals at a programmed basal rate and as a bolus; and

a controller programmed to receive the sensor glucose level signal and to provide a delivery control signal to the insulin delivery device to deliver the bolus and to set the programmed basal rate to zero for a predetermined period of time.

8. The system of claim 7 , wherein the predetermined period of time is based upon an amount of insulin delivered in a preceding closed-loop cycle.

9. The system of claim 7 , wherein the predetermined period of time is based upon a level of insulin on board (IOB) and the programmed basal delivery rate.

10. The system of claim 7 , wherein the bolus is an extended bolus.

11. The system of claim 10 , wherein the controller is further programmed to interrupt the extended bolus.

12. The system of claim 10 , wherein the controller is further programmed to interrupt the extended bolus based on if the patient is in a carbohydrate deficient state.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2018
From: WEI, CHARLES
To: ABBOTT DIABETES CARE INC.
Reel/Frame 046507/0605 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2018
From: BUDIMAN, ERWIN S.; HAYTER, GARY A.; CROUTHER, NATHAN; TAUB, MARC B.; HARPER, WESLEY SCOTT
To: ABBOTT DIABETES CARE INC.
Reel/Frame 046356/0927 →
Continuity (4)
Division 13601944 · Aug 31, 2012
Division 12785104 · May 21, 2010
Provisional Application 61180627 · May 22, 2009
Related Publication 20140180203A1 · Jun 26, 2014
Cited By (1)
US 12,380,981